We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Although infrequent, high use of short-acting beta 2 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Increasing exposure to short-acting beta 2 agonist ...
About one third of asthma patients have high use of short-acting beta agonists (SABAs) in Europe across all severity levels, said Santiago Quirce, MD, PhD, with Hospital Universitario in Madrid, Spain ...
Overuse of rescue medication among asthma patients is associated with increased exacerbations and higher total and asthma-related healthcare costs. Objective: To assess whether increased short-acting ...
I really didn't see the death of short-acting beta-agonists (SABAs) coming. Sure, I'd read the SYGMA trials, [1,2] and yes, I was aware of lobbying from the "other side of the pond" (Europe). [3] So I ...
This week, Dr Ray O’Connor takes a look at recent clinical articles on the management of asthma, and what environmental ...
In many patients, annual short-acting beta2-agonist prescription fulfillment is indicative of uncontrolled disease and increased incidence of exacerbations. Credit: Getty Images. Short-acting beta ...
Inhaled corticosteroid with short-acting β agonists or long-acting β agonist formoterol linked to reduction in exacerbations, improved control. HealthDay News — For patients with asthma, inhaled ...
WILMINGTON, Del.--(BUSINESS WIRE)--AIRSUPRA™ (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback